| Emtricitabine and Tenofovir Alafenamide Fumarate | Gilead | ||
| 200mg/ 25mg; Tablet |
More Than $1000 mn
|
||
|
More Than 5
|
More Than 5
|
||
|
More Than 5
|
Less Than 5
|
||
|
Less Than 5
|
None | ||
| DESCOVY is a two-drug combination of emtricitabine (FTC) and tenofovir alafenamide (TAF), both HIV nucleoside analog reverse transcriptase inhibitors (NRTIs), and is indicated: in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg. | |||
|
Yes
| |||
| Descovy | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 | Patent 13 | Patent 14 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ****** | *** ********* | *** ********* | ******* | ******* | ******* | ******* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) |
| ***** | *** ********* / ******* **** **** | *** ********* / ******* **** **** | ******* / ******* **** **** | ******* / ******* **** **** | ******* / *** ********* | ******* / *** ********* | *** ********* / **** ** *** **, **** | *** ********* / **** ** *** **, **** | *** ********* / **** ** *** **, **** | *** ********* / **** ** *** **, **** | *** ********* / **** ** *** **, **** | **** ** *** **, **** (***** ******) | **** ** *** **, **** (***** ******) | **** ** *** **, **** (***** ******) |
| ****** | *** ********* | *** ********* | ******* | ******* | ******* | ******* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| ****** | *** \ ********* | *** *, **** | ******* | ******** ************ | ** *** **, **** |
| ***** | *** \ ********* / *** *** ** ***(*)(*) | *** *, **** / *** **, **** | ******* / *** *** ******* | ********* ******** / **** | ** *** **, **** / *** ****** *** **** |
| ****** | *** \ ********* | *** *, **** | ******* | **** | ** *** **, **** |
| Emtricitabine and Tenofovir Alafenamide Fumarate | Gilead | ||
| 120mg/ 15mg; Tablet |
More Than $1000 mn
|
||
|
Less Than 5
|
Less Than 5
|
||
|
More Than 5
|
Less Than 5
|
||
|
Less Than 5
|
None | ||
| DESCOVY is a two-drug combination of emtricitabine (FTC) and tenofovir alafenamide (TAF), both HIV nucleoside analog reverse transcriptase inhibitors (NRTIs), and is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older. | |||
|
Yes
| |||
| Descovy | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ****** | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) |
| ***** | *** ********* / *** ********* | *** ********* / *** ********* | *** ********* / *** ********* | *** ********* / **** ** *** **, **** | *** ********* / **** ** *** **, **** | *** ********* / **** ** *** **, **** | *** ********* / **** ** *** **, **** | *** ********* / **** ** *** **, **** | **** ** *** **, **** (***** ******) | **** ** *** **, **** (***** ******) | **** ** *** **, **** (***** ******) |
| ******** ** *********** ********** ********* | ********* *********** ************ | ********* *********** ************ | **-********, ***** *** ***** ***** ** ********* *********** | ******* *** ********* ****-***** ********** ******* | ******* *** ********* ****-***** ********** ******* | ******* *** ********* ****-***** ********** ******* | ******* *** ********* ****-***** ********** ******* | ************** ************ ********** ********* *********** *** ************* | ************** ************ ********** ********* *********** *** ************* | ************** ************ ********** ********* *********** *** ************* |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| ****** | *** / *** | ** | *** ********* | ************ | ** *** **, **** |
| ***** | ** / ** / ***** *** *** ***(*)(*) | ** / *** **, **** | *** ********* / *** *** ******* | ********* ******** | ***** *** **** *********** / *** *** *** ****** *** **** |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|